Summaries of Key Journal Articles  by Eagle, Kim A. et al.
effects of RV pacing on LV size and function in patients
with bradycardia and a normal baseline EF.
Perspective: It would be inappropriate to routinely implant a
biventricular pacemaker in all bradycardic patients based on
this trial. First, RV pacing can be largely avoided with a
conventional dual-chamber pacemaker in patients with sinus
node dysfunction. Second, most patients with atrioventricu-
lar block do well clinically with RV dual-chamber pacing.
Serial echocardiograms can be used during follow-up to
identify the few patients who require upgrade to a biventric-
ular device.  
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Telephone-Delivered Collaborative Care for
Treating Post-CABG Depression: A Randomized
Controlled Trial
Rollman BL, Belnap BH, LeMenager MS, et al.
JAMA 2009;302:2095–2103.
Study Design: What is the effectiveness of telephone-delivered
collaborative care for post-coronary artery bypass grafting
(CABG) depression versus usual physician care?
Methods: A single-blind trial was conducted at seven univer-
sity-based and community hospitals in or near Pittsburgh, PA.
Participants were 302 post-CABG patients with depression
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Arrhythmias
Biventricular Pacing in Patients With Bradycardia
and Normal Ejection Fraction
Yu CM, Chan JY, Zhang Q, et al. 
N Engl J Med 2009;Nov 15:[Epub ahead of print].
Study Design: Does biventricular pacing prevent the deleterious
effects of right ventricular (RV) apical pacing in patients with
a normal ejection fraction (EF)?
Methods: In PACE, a double-blind, multicenter trial, 177
patients (mean age 68 years) with an EF >45% who had sinus
node dysfunction or atrioventricular block were randomly
assigned to biventricular (n = 89) or RV (n = 88) dual-cham-
ber pacing. The 1° endpoints were EF and left ventricular
end-systolic volume (LVESV) measured by echocardiography.
Results: The mean EF decreased significantly by an absolute
change of 6.7% in the RV pacing group and remained
unchanged in the biventricular pacing group. The EF at 12
months fell to <45% significantly more often in the RV pacing
(9%) than the biventricular pacing group (1%). The LVESV
increased significantly at 12 months by an absolute change of
7.1 ml (relative increase of 26%) in the RV pacing group and
was unchanged in the biventricular pacing group. There were
no significant differences in functional capacity, quality of life,
or heart failure hospitalizations at 12 months.
Conclusions: Biventricular pacing prevents the deleterious
renal artery revascularization in addition to medical therapy or
to medical therapy alone. Primary outcome was renal function.
Secondary outcomes were effects on blood pressure and num-
ber of blood pressure medications, time to renal and major
cardiovascular events, and mortality.
Results: During 5-year follow-up, the rate of progression of
renal impairment was -0.07 × 10−3 μmol/L per year in the
revascularization group compared with -0.13 × 10−3 μmol/L
per year in the medical therapy group, favoring revasculariza-
tion. Over the same time, the mean serum creatinine level was
1.6 μmol/L lower in the revascularization group. There was no
significant between-group difference in systolic blood pres-
sure; the decrease in diastolic blood pressure was smaller in
the revascularization group. Average number of antihyperten-
sive agents at 1 year was slightly higher for patients in the
medical therapy (2.97) versus the revascularization group
(2.77, p = 0.03). Importantly, the two groups had similar rates
of renal events, major cardiovascular events, and death. There
were a number (n = 23 patients) of serious complications asso-
ciated with revascularization, including two deaths and three
lower extremity amputations.
Conclusions: There is no evidence of a meaningful clinical ben-
efit from endovascular renal artery revascularization in
patients with atherosclerotic renovascular disease. However,
there appears to be a number of serious complications associ-
ated with an endovascular approach.
Perspective: Over the last decade, there has been a significant
increase in the number of patients with presumed renovas-
cular hypertension who undergo renal artery stenting and
angioplasty for renal artery stenosis. Concurrently, physi-
cians, mostly through multi-drug therapy, have been able to
attain reasonable blood pressures in most patients. This
large trial, which functionally documented no significant
long-term differences in outcomes, will perhaps dampen the
enthusiasm of many endovascular zealots. 
Summary written by: Gilbert Upchurch, Jr., MD 
General Cardiology
Extended-Release Niacin or Ezetimibe and Carotid
Intima-Media Thickness
Taylor AJ, Villines TC, Stanek EJ, et al. 
N Engl J Med 2009;Nov 15:[Epub ahead of print].
Study Question: What is the effect of niacin or ezetimibe on
common carotid intima-media thickness (CIMT) when
added to statin therapy?
Methods: In the ARBITER 6–HALTS trial, patients with
(150, intervention; 152, usual care) and a comparison group of
151 randomly sampled post-CABG patients without depres-
sion recruited between March 2004 and September 2007 and
observed as outpatients until June 2008. Eight months of tele-
phone-delivered collaborative care provided by nurses working
with patients’ primary care physicians and supervised by a psy-
chiatrist was compared to usual care by primary care
physicians. Primary outcome was mental health–related qual-
ity of life (HRQL) measured by the Short Form-36 Mental
Component Summary (SF-36 MCS) at 8-month follow-up.
Results: Of 2,485 patients completing a two-item Patient
Health Questionnaire (PHQ-2) prior to discharge, 1,387
(56%) were positive; 1,100 of those completed a PHQ-9 at 2
weeks, of which 30% had a score ≥10, and 302 were random-
ized to intervention or usual care. The intervention patients
reported greater improvements in mental HRQL (all p ≤
0.02), physical functioning, and mood symptoms; and were
more likely to report a 50% or greater decline in HRS-D
score from baseline (50.0% vs. 29.6%) than usual care patients
(p < 0.001). Men with depression were particularly likely to
benefit from the intervention (p = 0.001). However, the mean
HRQL and physical functioning of intervention patients did
not reach that of the nondepressed comparison group.
Conclusions: Compared with usual care, telephone-delivered
collaborative care for treatment of post-CABG depression
resulted in improved HRQL, physical functioning, and
mood symptoms at 8-month follow-up.
Perspective: Post-CABG depression is a well-known compli-
cation, particularly in men. The incidence of 2-week
post-CABG depressive symptoms was quite high in this
study. I suspect incident depressive symptoms would have
been lower and the benefits much less if the assessment and
intervention was delayed to 6-8 weeks, when patients’
HRQL related to postoperative status had improved. It is
important to screen for depression in all patients who have
experienced a cardiac event, which may improve HRQL as
well as compliance with lifestyle change and treatments. 
Summary written by: Melvyn Rubenfire, MD 
Revascularization Versus Medical Therapy for
Renal-Artery Stenosis
The ASTRAL Investigators.
N Engl J Med 2009;361:1953–1962.
Study Design: What are the clinical benefits of percutaneous
renal artery revascularization compared with modern, best
medical therapy?
Methods: A total of 806 patients with mostly severe atheroscle-
rotic renovascular disease were randomized to undergo either
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cohort of 123,407 adults starting dialysis and receiving fol-
low-up for a mean of 1.8 years. The outcome measure of
death was compared with the European general population.
Standardized CV and non-CV mortality rates, their ratio,
difference, and relative excess of CV over non-CV mortal-
ity were calculated. 
Results: During follow-up, 25,084 patients (20.3%) were
censored because of kidney transplantation, and 42,643
(34.6%) died. Overall all-cause mortality rates in patients
and the general population were 192 per 1,000  and 12.06
per 1,000 person-years, respectively. Cause of death was
known for 90% of the patients and 99% of the general pop-
ulation. In patients, 16,654 deaths (39%) were CV and
21,654 (51%) were non-CV, similar to the general popula-
tion. CV and non-CV mortality rates in patients were
respectively 38.1 per 1,000 and 50.1 per 1,000 person-years
higher than in the general population. Standardized CV and
non-CV mortality were respectively 8.8 and 8.1 times
higher than in the general population.
Conclusions: Patients starting dialysis have an increased risk of
death that is not specifically caused by excess CV mortality.
Perspective: The mortality rate of 35% in 3 years was distrib-
uted similarly between CV disease (CVD) and non-CVD as
in the general population (45% CVD and 55% non-CVD).
The increase in CVD deaths in ESRD is attributable mostly
to an increase in hypertension, diabetes, inflammatory milieu,
and effects of uremia and possibly dialysis on vascular calcifi-
cation. The failure of high-dose statins to lower the CV
mortality in patients on dialysis was a major surprise.  
Summary written by: Melvyn Rubenfire, MD
Statin Use and Risk of Gallstone Disease Followed
by Cholecystectomy 
Bodmer M, Brauchli YB, Krahenbuhl S, Jick SS, Meier CR.
JAMA 2009;302:2001–2007. 
Study Question: What is the association between use of
statins, fibrates, or other lipid-lowering agents and risk of
incident gallstone disease followed by cholecystectomy? 
Methods: Case-control analysis was performed using the UK-
based General Practice Research Database. Incident patients
between 1994 and 2008 and four controls per each patient
were identified and matched on age, sex, general practice, cal-
endar time, and years of history in the database. Conditional
logistic regression was used to estimate the odds ratio (OR) of
developing gallstones followed by cholecystectomy in relation
to exposure to lipid-lowering agents, stratified by exposure
timing and duration.
coronary heart disease, who were receiving long-term statin
therapy, with a low-density lipoprotein (LDL) cholesterol
under 100 mg/dl and a high-density lipoprotein (HDL) cho-
lesterol under 50 mg/dl for men or 55 mg/dl for women were
randomly assigned to receive extended-release niacin (target
dose, 2000 mg/day) or ezetimibe (10 mg/day). The primary
endpoint was change in CIMT after 14 months. The trial was
terminated early, on the basis of efficacy, after 208 patients
had completed the trial.
Results: The mean HDL in the niacin group increased by
18.4% over 14 months, to 50 mg/dl (p < 0.001), and the
mean LDL in the ezetimibe group decreased by 19.2%, to 66
mg/dl (p < 0.001). Niacin therapy significantly reduced LDL
and triglycerides whereas ezetimibe reduced the HDL and
triglycerides. Compared with ezetimibe, niacin had greater
efficacy regarding the change in mean CIMT over 14 months
(p = 0.003), leading to significant reduction of both mean (p =
0.001) and maximal CIMT (p ≤ 0.001 for all comparisons).
Paradoxically, greater reductions in LDL cholesterol in asso-
ciation with ezetimibe were significantly associated with an
increase in the CIMT (p < 0.001). The incidence of major
cardiovascular events was lower in the niacin group. 
Conclusions: The use of extended-release niacin causes signifi-
cant regression of CIMT when combined with a statin, and
niacin is superior to ezetimibe.
Perspective: This is a relatively small study not powered for
clinical events; however, the results support strong considera-
tion of combined treatment with statins and niacin for
reduction of vascular risk in patients at high risk for events and
low HDL. Taken together with other studies, it is clear that
not all LDL-lowering or HDL-raising treatments will have
the same effect on vascular risk. Each class of therapy will
need to be tested in clinical event trials.  
Summary written by: Daniel T. Eitzman, MD
Cardiovascular and Noncardiovascular Mortality
Among Patients Starting Dialysis
de Jager DJ, Grootendorst DC, Jager KJ, et al. 
JAMA 2009;302:1782–1789.
Study Question: Cardiovascular (CV) mortality is considered
the main cause of death in patients receiving dialysis and is
10 to 20 times higher in such patients than in the general
population. Is the high overall mortality in patients with
end-stage renal disease (ESRD) starting dialysis a conse-
quence of increased CV mortality risk only, or is non-CV
mortality equally increased?
Methods: Using data from January 1, 1994 to January 1,
2007, the authors age-stratified mortality in a European
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Results: A total of 27,035 patients with cholecystectomy and
106,531 matched controls were identified, including 2,396
patients and 8,868 controls who had statin use. Compared
with nonuse, current statin use was 1.0% for patients and
0.8% for controls for 1-4 prescriptions, 2.6% versus 2.4% for
5-19 prescriptions, and 3.2% versus 3.7% for 20 or more
prescriptions. The adjusted ORs for current use of statins
defined as 20 or more prescriptions were similar (around
0.6) across age, sex, and body mass index categories, and
across the statin class. Current long-term use of fibrates was
associated with a slightly increased adjusted OR of 1.39 for
developing gallstones followed by cholecystectomy.
Conclusions: Long-term use of statins was associated with a
decreased risk of gallstones followed by cholecystectomy.
Perspective: Cholesterol gallstones are the most common and
may be reduced by the statin’s effect of decreasing hepatic
cholesterol biosynthesis and decrease in cholesterol concentra-
tion in bile. The ability to significantly reduce the prevalence
of gallstones should be added to the potential cost-effective-
ness of statins, the most cost-effective life-saving agents short
of treatment of infection. The increase in gallstones associated
with fibrates has been demonstrated in clinical trials.  
Summary written by: Melvyn Rubenfire, MD 
Cardiovascular Diseases and Risk of Hip Fracture
Sennerby U, Melhus H, Gedeborg R, et al.
JAMA 2009;302:1666–1673. 
Study Question: Is there an association between cardiovascular
disease (CVD) and risk of hip fracture, and if so, is this
association due to genetic or lifestyle factors?
Methods: This analysis of data from the National Twin
Registry in Sweden included twins born between 1914 and
1944. Among 15,968 twin pairs, the authors used the
Swedish National Patient Registry to identify cases of
CVD, hip fracture, and comorbidities between 1964 and
2005. CVD was broken down into heart failure (HF),
stroke (CVA), ischemic heart disease (CAD), and periph-
eral artery disease (PAD).
Results: The rate of hip fracture was increased after diagnosis
of CVD, to 12.6 per 1,000 person-years after a diagnosis of
HF; 12.6 per 1,000 after CVA; 6.6 per 1,000 after PAD; and
5.2 per 1,000 after CAD; compared with 1.2 per 1,000 per-
son-years for those without CVD. Adjusted hazard ratio
(HR) for hip fracture after HF was 4.40, after CVA 5.09,
after PAD 3.20, and after CAD 2.32. Identical twins whose
sibling developed CVD also had increased risk of hip fracture,
with HR 3.74 for hip fracture associated with sibling HF, and
HR 2.29 after sibling CVA.
Conclusions: A diagnosis of CVD is associated with a signifi-
cantly increased risk of subsequent hip fracture. Also, the
increased hip fracture risk associated with co-twin diagnosis
of CVD suggests that genetic factors are involved in the
association.
Perspective: The authors identified numerous risk factors for
hip fracture that differed significantly between those with
CVD and those without. They rigorously adjusted for these
factors, but one wonders if unappreciated confounders could
exist. Overall, the authors make an excellent argument for an
increased risk of hip fracture in CVD patients, and a well-
supported recommendation to assess hip fracture risk in CVD
patients. Of even greater interest is the possible biological link
between CVD and hip fracture—whether genetic or environ-
mental—that could lead to better prevention.  
Summary written by: James B. Froehlich, MD  
A Trial of Darbepoetin Alfa in Type 2 Diabetes and
Chronic Kidney Disease
Pfeffer MA, Burdmann EA, Chen CY, et al., on behalf of the TREAT
Investigators.
N Engl J Med 2009;361:2019–2032.
Study Question: What is the effect of darbepoetin alfa on clini-
cal outcomes in patients with type 2 diabetes, chronic kidney
disease, and anemia?
Methods: A total of 4,038 patients with diabetes, chronic kid-
ney disease, and anemia were randomly assigned to receive
either darbepoetin alfa (n = 2,012) to achieve a hemoglobin
level of approximately 13 g/dl or placebo (n = 2,026), with
rescue darbepoetin alfa when the hemoglobin was less than
9.0 g/dl. Primary endpoints were the composite outcomes of
death or a cardiovascular (CV) event and of death or end-
stage renal disease. 
Results: Death or a CV event occurred in 632 patients
assigned to darbepoetin alfa and 602 patients assigned to
placebo. Death or end-stage renal disease occurred in 652
patients assigned to darbepoetin alfa and 618 patients
assigned to placebo. Fatal or nonfatal stroke occurred in 101
patients assigned to darbepoetin alfa and 53 patients
assigned to placebo. Red-cell transfusions were administered
to 297 patients assigned to darbepoetin alfa and 496 patients
assigned to placebo. There was only a modest improvement
in patient-reported fatigue in the darbepoetin alfa group
compared with placebo.
Conclusions: Use of darbepoetin alfa in patients with diabetes,
chronic kidney disease, and moderate anemia who are not
undergoing dialysis does not reduce composite risks of death
JACC Vol. 55, No. 1, 2010
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function and intolerance to ACE inhibitors compared with
losartan 50 mg daily.
Perspective: This study demonstrates that high-dose losartan
is superior to the lower dose in those intolerant to ACE
inhibitors. It is unclear why only 72% of the study cohort
was on beta-blockers despite having significant systolic dys-
function. The losartan was discontinued in ~27% of patients
in both groups, suggesting one in four of the ACE-intoler-
ant patients do not tolerate ARBs. The increased incidence
of azotemia and hyperkalemia in both groups suggests that
careful monitoring of renal function and electrolytes will be
required when up-titrating the ARB dose.  
Summary written by: Ragavendra R. Baliga, MBBS 
Ferric Carboxymaltose in Patients With Heart
Failure and Iron Deficiency
Anker SD, Colet JC, Filippatos G, et al., on behalf of the FAIR-HF Trial
Investigators.
N Engl J Med 2009;Nov 17:[Epub ahead of print].
Study Question: Does treatment with intravenous iron (ferric
carboxymaltose) improve symptoms in systolic heart failure
(HF) and iron deficiency, either with or without anemia?
Methods: The FAIR-HF trial investigators enrolled 459
patients with New York Heart Association (NYHA) func-
tional class II or III HF, left ventricular ejection fraction
≤40% (for patients with NYHA class II) or ≤45% (for
NYHA class III), iron deficiency, and hemoglobin of 95-
135 g/L. They randomly assigned patients, in a 2:1 ratio, to
receive 200 mg of ferric carboxymaltose or saline (placebo).
Primary endpoints were the self-reported Patient Global
Assessment and NYHA functional class, both at week 24.
Results: Half of the patients receiving ferric carboxymaltose
reported being much or moderately improved, as compared
with 28% of patients receiving placebo; 47% of the patients on
ferric carboxymaltose had an NYHA functional class I or II at
week 24, as compared with 30% of patients on placebo (odds
ratio for improvement by one class, 2.40). Results were similar
in patients with anemia and without anemia. Significant
improvements in the distance on the 6-minute walk test and
quality-of-life assessments were seen with ferric carboxymal-
tose. The mortality rate, adverse events, and serious adverse
events were similar in both study groups. 
Conclusions: Therapy with intravenous ferric carboxymaltose in
HF patients with iron deficiency, with or without anemia,
improves symptoms, functional capacity, and quality of life.
Perspective: This is the third study that suggests iron replace-
ment therapy may be beneficial in iron deficient HF
or CV event, or death or renal event, and is associated with
an increased risk of stroke.
Perspective: Because of clinical benefits presumed to occur
with correction of anemia with recombinant versions of ery-
thropoietin, previous trials with erythropoiesis-stimulating
agents did not contain placebo groups. Although there was a
modest effect of darbepoetin alfa treatment on fatigue in the
current trial, there was no effect of treatment on death,
renal, or CV events, and a highly significant twofold increase
in the risk of stroke. This study highlights the critical
importance of placebo-controlled clinical trials in establish-
ing the relative risks versus benefits of therapeutic
interventions.  
Summary written by: Daniel T. Eitzman, MD 
Heart Failure/Transplant
Effects of High-Dose Versus Low-Dose Losartan on
Clinical Outcomes in Patients With Heart Failure
(HEAAL Study): A Randomized, Double-Blind Trial
Konstam MA, Neaton JD, Dickstein K, et al.
Lancet 2009;374:1840–8.
Study Question: How does high-dose losartan (an angiotensin-
receptor blocker [ARB]) compare versus low-dose losartan
on clinical outcomes in patients with heart failure (HF)?
Methods: HEAAL was a double-blind randomized trial,
which included 3,846 HF patients with New York Heart
Association (NYHA) class II-IV, LVEF ≤40%, and intoler-
ance to angiotensin-converting enzyme (ACE) inhibitors.
Patients were randomly assigned to losartan 150 mg (n =
1,927) or 50 mg daily (n = 1,919). The primary endpoint
was death or admission for HF. The median follow-up was
4.7 years. About 70% of the patients were NYHA class II
heart failure and approximately 70% had hypertension.
Results: The investigators found that 43% (n = 828) of
patients in the 150 mg group versus 46% (n = 889) in the 
50 mg group died or were admitted for HF. For the two pri-
mary endpoint components, 635 patients in the 150 mg
group versus 665 in the 50 mg group died, and 450 versus
503 patients were admitted for HF. Renal impairment 
(n = 454 vs. 317), hypotension (203 vs. 145), and hyper-
kalemia (195 vs. 131) were more common in the 150 mg
group, but did not lead to significantly more treatment dis-
continuations.
Conclusions: Losartan 150 mg daily reduced the rate of death
or admission for HF in patients with HF due to systolic dys-
86 Eagle, Cannon
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regardless of the presence or absence of anemia. Larger
studies evaluating the impact of such therapy on survival will
be required before such therapy can be recommended for
routine use. I am interested to know whether oral iron is
comparable to intravenous iron.  
Summary written by: Ragavendra R. Baliga, MBBS  
Advanced Heart Failure Treated With Continuous-
Flow Left Ventricular Assist Device
Slaughter MS, Rogers JG, Milano CA, et al., on behalf of the 
HeartMate II Investigators.
N Engl J Med 2009;Nov 17:[Epub ahead of print].
Study Question: How does the newer HeartMate II left ven-
tricular assist device (LVAD; a continuous-flow device)
compare with the older more durable HeartMate XVE (a
pulsatile-flow device)?
Methods: The HeartMate II study was a randomized trial
that enrolled patients with advanced heart failure who were
ineligible for cardiac transplantation, in a 2:1 ratio, to
undergo implantation of a continuous-flow device (n = 134)
or the pulsatile-flow device (n = 66). The primary compos-
ite endpoint included survival free from disabling stroke
and reoperation to repair or replace the device at the end of
2 years.
Results: The preoperative characteristics were similar in both
treatment groups, with a median age of 64 years, mean left
ventricular ejection fraction of 17%, and nearly 80% of the
study cohort receiving intravenous inotropes. The primary
composite endpoint was achieved in more patients with con-
tinuous-flow devices than with pulsatile-flow devices (62 of
134 [46%] vs. 7 of 66 [11%]; p < 0.001), and patients with
continuous-flow devices had superior actuarial survival rates at
2 years (58% vs. 24%, p = 0.008). There were less adverse
events and device replacements were less frequent in patients
with the continuous-flow device. 
Conclusions: Therapy with a continuous-flow LVAD in
patients with advanced heart failure significantly improved
the probability of survival free from stroke and device fail-
ure at 2 years compared with a pulsatile device. Both
devices significantly improved quality of life and functional
capacity.
Perspective: When the smaller continuous-flow LVADs were
initially introduced, intuitively heart failure physicians and
patients knew that these devices would be associated with a
better quality of life. This study confirms these sentiments,
and demonstrates that these devices are more robust than
pulsatile LVADs, suggesting they may be suitable for desti-
nation therapy. An important advantage of the continuous-
flow LVADs is that they can be implanted in smaller
individuals not eligible for the larger devices.  
Summary written by: Ragavendra R. Baliga, MBBS  
Efficacy and Economic Assessment of Conventional
Ventilatory Support Versus Extracorporeal
Membrane Oxygenation for Severe Adult Respiratory
Failure (CESAR): A Multicentre Randomised
Controlled Trial
Peek GJ, Mugford M, Tiruviopati R, et al., on behalf of the CESAR Trial
Collaboration.
Lancet 2009;374:1351–1363.
Study Question: What is the safety, clinical efficacy, and cost-
effectiveness of extracorporeal membrane oxygenation
(ECMO) compared with conventional ventilation support?
Methods: Of the 766 patients screened, the investigators ran-
domized 180 adults to receive continued conventional
management (n = 90) or referral to consideration for treat-
ment by ECMO (n = 90). Inclusion criteria were ages 18-65
years and had severe, but potentially reversible respiratory
failure. Patients were excluded when high pressure (>30 cm
H2O of peak inspiratory pressure) or high FiO2 (>0.8) ven-
tilation for >7 days, intracranial bleeding, any other
contraindication to limited heparin therapy, or to continua-
tion of active treatment. The primary outcome was mortality
or severe disability at 6 months after randomization or
before discharge from the hospital.
Results: Seventy-five percent (n = 68) of patients actually
received ECMO, and 63% of patients allocated to consider-
ation for treatment by ECMO survived to 6 months
without disability when compared with 47% of those allo-
cated to conventional management (p = 0.03). Referral to
consideration for ECMO treatment led to a gain of 0.03
QALYs at 6-month follow-up. A lifetime model predicted
the cost per QALY of ECMO to be £19 252 at a discount
rate of 3.5%.
Conclusions: The investigators recommend transferring patients
with severe but potentially reversible respiratory failure to a
center with an ECMO-based management protocol to reduce
mortality without severe disability. This approach is cost-
effective in settings with similar services to those in the
United Kingdom (UK).
Perspective: Murray’s score has traditionally been used to
determine prognosis in acute respiratory distress syndrome
(ARDS). This article is important because it suggests that
JACC Vol. 55, No. 1, 2010
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Murray’s score can also be used to make therapeutic choices
for ARDS, in particular, the use of ECMO. I have seen
patients with ARDS due to H1N1 virus, and one immediate
potential application is in making choices regarding ECMO
in such patients. More data are required to determine
whether the cost-benefit analysis seen in the UK is applica-
ble to the US health care system.  
Summary written by: Ragavendra R. Baliga, MBBS 
Interventional Cardiology
C-Reactive Protein and the Risk of Stent
Thrombosis and Cardiovascular Events After Drug-
Eluting Stent Implantation
Park DW, Yun SC, Lee JY, et al.
Circulation 2009;120:1987–1995.
Study Question: What is the predictive usefulness of C-reac-
tive protein (CRP) among patients treated with drug-eluting
stents (DES)?
Methods: The authors prospectively evaluated 2,691 patients
treated with DES who had a baseline CRP measurement.
The primary outcome was stent thrombosis; secondary out-
comes were death, myocardial infarction (MI), death or MI,
and target vessel revascularization.
Results: During follow-up (median 3.9 years), 32 patients
had definite or probable stent thrombosis, 137 patients died,
227 had an MI, and 195 underwent target vessel revascular-
ization. Elevated levels of CRP were significantly associated
with increased risk of stent thrombosis (p < 0.001). Elevated
CRP levels also significantly predicted the risks of death 
(p = 0.008), MI (p = 0.001), and death or MI (p < 0.001),
but not target vessel revascularization (p = 0.21).
Incorporation of CRP into a model with patient, lesion, and
procedural factors resulted in a significant increase in the C
statistic for the prediction of stent thrombosis, MI, and the
composite of death or MI.
Conclusions: Elevated CRP levels were significantly associated
with increased risks of stent thrombosis, death, and MI in
patients receiving DES.
Perspective: Inflammatory risk stratification with CRP as an
adjunct to clinical and angiographic risk factors may be poten-
tially useful for the identification of high-risk patients, and
there may be potential for risk reductions with preventive
interventions that modulate CRP levels. The present study
does not address the clinical value of lowering CRP levels, and
the findings should not be construed as implying a benefit of
reducing CRP itself after DES implantation. Additional
prospective studies are needed.  
Summary written by: Debabrata Mukherjee, MD 
Platelet Inhibition With Cangrelor in Patients
Undergoing PCI
Harrington RA, Stone GW, McNulty S, et al., on behalf of the
CHAMPION PCI Investigators.
N Engl J Med 2009;Nov 15:[Epub ahead of print].
Study Question: What is the benefit of cangrelor, a reversible
adenosine diphosphate (ADP) receptor antagonist, in
patients undergoing percutaneous coronary intervention
(PCI)?
Methods: The CHAMPION PCI authors randomized 8,877
patients with acute coronary syndromes to cangrelor or 600
mg of oral clopidogrel administered before PCI. The pri-
mary efficacy endpoint was a composite of death from any
cause, myocardial infarction, or ischemia-driven revascular-
ization at 48 hours.
Results: There was no difference in the occurrence of the
primary endpoint at 48 hours (7.5% in the cangrelor group
and 7.1% in the clopidogrel group, p = 0.59). Likewise, no
difference in outcome was noted at 30 days. The rate of
major bleeding was higher with cangrelor (3.6% vs. 2.9%; p
= 0.06), but there was no excess of TIMI or GUSTO
bleeding.
Conclusions: Use of periprocedural cangrelor during PCI was
not superior to placebo in reducing death, myocardial
infarction, or ischemia-driven revascularization.
Perspective: The two CHAMPION studies (see the next
Journal Scan) failed to demonstrate a reduction in the pri-
mary endpoint with cangrelor when it was compared with
placebo or with clopidogrel. The reduction in secondary
endpoints in CHAMPION PLATFORM is interesting,
but the possibility of a type A error cannot be ruled out.
Further, the lack of such a signal in CHAMPION PCI
where the drug was compared with clopidogrel suggests that
the same benefit (if any) may potentially be achieved with
preloading with clopidogrel. The drug was also associated
with an increase in major bleeding, suggesting an unfavor-
able risk–benefit profile. Further, the release of prasugrel
and the strongly positive data supporting ticagrelor have
changed the market dynamics and I would be surprised if
the sponsors choose to pursue further development of 
this agent.  
Summary written by: Hitinder S. Gurm, MBBS 
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Intravenous Platelet Blockade With Cangrelor
During PCI
Bhatt DL, Lincoff AM, Gibson CM, et al., on behalf of the 
CHAMPION PLATFORM Investigators.
N Engl J Med 2009;Nov 15:[Epub ahead of print].
Study Question: What is the benefit of cangrelor, a reversible
adenosine diphosphate (ADP) receptor antagonist, in
patients undergoing percutaneous coronary intervention
(PCI)?
Methods: The CHAMPION PLATFORM authors random-
ized 5,362 patients who had not been treated with clopidogrel
to receive either cangrelor or placebo at the time of PCI, fol-
lowed by 600 mg of clopidogrel. The primary endpoint was a
composite of death, myocardial infarction, or ischemia-driven
revascularization at 48 hours.
Results: There was no difference in the occurrence of the pri-
mary endpoint between the two groups (7.0% in the
cangrelor arm vs. 8% in the placebo arm, p = 0.17). There
was a reduction in two secondary endpoints with cangrelor;
the rate of stent thrombosis and rate of death, both at 48
hours. There was no significant difference in the rate of
blood transfusion (1.0% in the cangrelor group vs. 0.6% in
the placebo group, p = 0.13), although major bleeding on the
ACUITY scale was increased in the cangrelor group, from
3.5% to 5.5% (p < 0.001), because of more groin hematomas.
Conclusions: The use of periprocedural cangrelor during PCI
was not superior to placebo in reducing the primary end-
point.
Perspective: (Refer to the preceding Journal Scan on 
CHAMPION PCI for the same Perspective).  
Summary written by: Hitinder S. Gurm, MBBS
Prevention/Vascular 
A Selective Endothelin-Receptor Antagonist to
Reduce Blood Pressure in Patients With
Treatment-Resistant Hypertension: A Randomised,
Double-Blind, Placebo-Controlled Trial
Weber MA, Black H, Bakris G, et al.
Lancet 2009;374:1423–1431.
Study Question: What is the blood pressure-lowering effect of
the new vasodilatory, selective endothelin type A antagonist,
darusentan, in patients with treatment-resistant hyperten-
sion?
Methods: A randomized, double-blind study was undertaken in
117 sites in North and South America, Europe, New
Zealand, and Australia. A total of 379 patients with systolic
blood pressure of 140 mm Hg or more who were receiving at
least three blood pressure-lowering drugs, including diuretic,
at full or maximum tolerated doses were randomly assigned to
14 weeks’ treatment with placebo (n = 132) or darusentan 50
mg (n = 81), 100 mg (n = 81), or 300 mg (n = 85) taken once
daily. Primary endpoints were changes in sitting systolic and
diastolic blood pressures.
Results: Almost all patients were on angiotensin-converting
enzyme inhibitors or angiotensin-receptor blockers and a
diuretic, calcium-channel blockers were used in about 75%,
and two-thirds were taking a beta-blocker. The mean
reductions in clinic systolic and diastolic blood pressures
were 9/5 mm Hg with placebo, 17/10 mm Hg with
darusentan 50 mg, 18/10 mm Hg with darusentan 100 mg,
and 18/11 mm Hg with darusentan 300 mg (p < 0.0001 for
all effects). The main adverse effects were related to fluid
accumulation. Edema or fluid retention occurred in 67
(27%) patients given darusentan compared with 19 (14%)
given placebo. One patient in the placebo group died (sud-
den cardiac death), and five patients in the three
darusentan dose groups combined had cardiac-related seri-
ous adverse events.
Conclusions: Darusentan provides additional reduction in
blood pressure in patients who have not attained their treat-
ment goals with three or more antihypertensive drugs. Fluid
management with effective diuretic therapy might be
needed.
Perspective: The added benefit of darusentan is highly rele-
vant, but I believe the edema will be a significant deterrent
to widespread use. The long-term efficacy and safety as well
as impact on vascular event rates and renal function will
need to be assessed. Whether the edema associated with
darusentan represents redistribution of fluid or microvascu-
lar leak as with the dihydropyridines or decrease in renal
blood flow is not known, but the weight gain was modest
compared to placebo.  
Summary written by: Melvyn Rubenfire, MD
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